Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,230
Employees2,230
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,230
Employees2,230

ALNY Key Statistics

Market cap
59.84B
Market cap59.84B
Price-Earnings ratio
1.85K
Price-Earnings ratio1.85K
Dividend yield
Dividend yield
Average volume
1.00M
Average volume1.00M
High today
$453.99
High today$453.99
Low today
$444.43
Low today$444.43
Open price
$448.05
Open price$448.05
Volume
68.90K
Volume68.90K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $452.94. The company's market cap stands at 59.84B, with a P/E ratio of 1851.58.

As of 2025-11-28, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $444.43 and $453.99. The current price stands at $452.94, placing the stock +1.9% above today's low and -0.2% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 68.9K, compared to an average daily volume of 1M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

ALNY News

Nasdaq 4d
Validea Detailed Fundamental Analysis - ALNY

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Quantitat...

Validea Detailed Fundamental Analysis - ALNY
Simply Wall St 4d
Is Alnylam Pharmaceuticals Stock Justified After 73.9% Surge and Clinical Trial Milestones?

Wondering if Alnylam Pharmaceuticals stock offers real value, or if recent momentum has left the price running ahead of its fundamentals? You're definitely not...

Is Alnylam Pharmaceuticals Stock Justified After 73.9% Surge and Clinical Trial Milestones?

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.